AbCellera reports positive ABCL635 phase 2 results
Phase 2 trial of ABCL635 met primary endpoints for hot flash reduction. The results mark a new efficacy benchmark for the treatment of vasomotor symptoms.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day